No Data
Beijing Balance Medical Technology Co., Ltd. (688198.SH): The registration application for ophthalmic biological patches has been accepted.
beijing balance medical technology co., ltd. (688198.SH) announced that the registration application of the ophthalmic biological patch product developed by the company has been approved recently...
Beijing Balance Medical Technology Co., Ltd. (688198.SH): Application for pericardial membrane registration has been accepted.
Gelonghui, November 19 - Beijing Balance Medical Technology Co., Ltd. (688198.SH) announced that the registration application for the ePTFE pericardium developed by the company has been officially accepted by the National Medical Products Administration. This product is manufactured using a special process to create an expanded polytetrafluoroethylene (ePTFE) membrane, which is used for the repair or reconstruction of the pericardium in cardiac surgery.
Bairen Healthcare Third Quarter Report 2024
beijing balance medical technology co., ltd. (688198.SH): The net income in the first three quarters was 58.6934 million yuan, a year-on-year decrease of 16.56%.
On October 29, beijing balance medical technology co., ltd. (688198.SH) announced that in the first three quarters of 2024, it achieved a total operating income of 0.292 billion yuan, a year-on-year increase of 13.57%; the net income attributable to shareholders of the parent company decreased by 16.56% to 58.6934 million yuan; the basic earnings per share was 0.43 yuan.
Has the source of funds for the controlling shareholder's shareholding changed? Beijing Balance Medical Technology Co., Ltd. insider: Self-financing can also be done through "special shareholding loans".
①Company insiders have expressed that beijing balance medical technology co., ltd. plans to increase its shareholding through self-raised funds, not ruling out the possibility of increasing company stocks through bank's "stock shareholding special loans". ②Jin Lei, the director of beijing balance medical technology co., ltd., believes that against the backdrop of a sluggish performance in the medical instruments sector, the company's stock price is undervalued by the market.
The first case! The controlling shareholder of a listed company intends to increase shareholding by borrowing money. The latest response from beijing balance medical technology co., ltd. has arrived.
① Economist Song Qinghui stated that the interest rates of special loans are relatively low, but if a listed company fails to repay the debt within the specified time, they may face higher financing costs and financial pressure. ② Jin Lei believes that beijing balance medical technology co., ltd. has entered a stage of steady development. As a major shareholder of the company, the annual shareholder dividends can fully cover loan interest, avoiding financial risks caused by loans from banks.
